Status:
COMPLETED
A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927
Lead Sponsor:
UCB Pharma
Conditions:
Epilepsy
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this trial was to evaluate the safety and tolerability of SPM 927 when given as iv infusions compared with oral administration of the same dose strengths in subjects who were receiving ...
Eligibility Criteria
Inclusion
- Subject with partial seizures with or without secondary generalization
Exclusion
- Subject had previously received iv SPM 927
- Subject met the withdrawal criteria for the open-label extension trial with SPM 927 or was experiencing an ongoing serious adverse event.
Key Trial Info
Start Date :
March 4 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2004
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00800215
Start Date
March 4 2004
End Date
November 30 2004
Last Update
April 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.